Development of surface-engineered PLGA nanoparticulate-delivery system of Tet1-conjugated nattokinase enzyme for inhibition of Aβ(40) plaques in Alzheimer’s disease

According to the World Health Organization, globally there are around 18 million patients suffering from Alzheimer’s disease (AD), and this number is expected to double by 2025. The pathophysiology of AD includes selective deposition of Aβ peptide in the mitochondria of cells, which inhibits uptake...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatt, Prakash Chandra, Verma, Amita, Al-Abbasi, Fahad A, Anwar, Firoz, Kumar, Vikas, Panda, Bibhu Prasad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732557/
https://www.ncbi.nlm.nih.gov/pubmed/29263666
http://dx.doi.org/10.2147/IJN.S144545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732557/
https://www.ncbi.nlm.nih.gov/pubmed/29263666
http://dx.doi.org/10.2147/IJN.S144545

Ejemplares similares